Literature DB >> 3449480

Squamous cell carcinoma of the pyriform sinus: retrospective study of 351 cases treated at the Institut Gustave-Roussy.

C Vandenbrouck1, F Eschwege, A De la Rochefordiere, H Sicot, G Mamelle, A M Le Ridant, J Bosq, C Domenge.   

Abstract

The first part of the study was devoted to 199 tumors treated by surgery, either conservative for the smallest tumors (18 cases) or radical (181 cases), with systematic postoperative radiotherapy. The 3-year survival rate was 48% and the 5-year, 33%, with a 12% local recurrence rate, a 7.5% neck recurrence rate, and 27.6% rate distant metastases. Histologic correlations were developed. The second part of the study reported 152 cases treated by external radiotherapy alone either as a variant of our treatment protocol for the small-sized tumors (31 cases) or, for the major part (121 cases), as a result of surgical inoperability or patient refusal. The former subgroup had a variable survival rate (65% at 3 years and 40% at 5 years) equivalent to similarly staged patients treated with conservation laryngeal surgery, whereas the prognosis of the latter subgroup was poor. The two main causes of failure were the inability to apply the curative treatment protocol in 35% of patients ineligible for a surgery and the high risk of distant metastases in the 65% of patients able to undergo the usual management.

Entities:  

Mesh:

Year:  1987        PMID: 3449480     DOI: 10.1002/hed.2890100103

Source DB:  PubMed          Journal:  Head Neck Surg        ISSN: 0148-6403


  8 in total

1.  Primary radiotherapy for squamous cell carcinoma of the pyriform sinus.

Authors:  William M Mendenhall; Robert J Amdur; Christopher G Morris; Jessica Kirwan; Peter T Dziegielewski; John W Werning
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-14       Impact factor: 2.503

2.  p62/SQSTM1 levels predicts radiotherapy resistance in hypopharyngeal carcinomas.

Authors:  Akihito Arai; Tokuhiro Chano; Kaichiro Ikebuchi; Yusuke Hama; Yasuko Ochi; Hitosuke Tameno; Taketoshi Shimada
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

3.  Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma.

Authors:  B J M Braakhuis; A Senft; R de Bree; J de Vries; B Ylstra; J Cloos; D J Kuik; C R Leemans; R H Brakenhoff
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

4.  A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.

Authors:  J J Beitler; R V Smith; H Haynes; C E Silver; A Quish; T Kotz; M Serrano; A Brook; S Wadler
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

5.  Oncological outcome after free jejunal flap reconstruction for carcinoma of the hypopharynx.

Authors:  Jimmy Yu Wai Chan; Velda Ling Yu Chow; Richie Chiu Lung Chan; Gregory Ian Siu Kee Lau
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-18       Impact factor: 2.503

6.  Silencing Snail Reverses Epithelial-Mesenchymal Transition and Increases Radiosensitivity in Hypopharyngeal Carcinoma.

Authors:  HaiYan Wang; ZhiHai Wang; YanShi Li; Tao Lu; GuoHua Hu
Journal:  Onco Targets Ther       Date:  2020-01-16       Impact factor: 4.147

7.  Treatment outcomes of definitive chemoradiotherapy for patients with hypopharyngeal cancer.

Authors:  Rie Nakahara; Takeshi Kodaira; Kazuhisa Furutani; Hiroyuki Tachibana; Natsuo Tomita; Haruo Inokuchi; Nobutaka Mizoguchi; Yoko Goto; Yoshiyuki Ito; Shinji Naganawa
Journal:  J Radiat Res       Date:  2012-07-22       Impact factor: 2.724

8.  Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers.

Authors:  Katsumaro Kubo; Yuji Murakami; Masahiro Kenjo; Nobuki Imano; Yuki Takeuchi; Ikuno Nishibuchi; Tomoki Kimura; Daisuke Kawahara; Tsutomu Ueda; Sachio Takeno; Yasushi Nagata
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.